# An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects

> **NCT02205905** · PHASE1 · COMPLETED · sponsor: **Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 14C PER977

## Key facts

- **NCT ID:** NCT02205905
- **Lead sponsor:** Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02205905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02205905, "An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02205905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*